Adjuvant DIBROMODULCITOL (cas 10318-26-0) and BCNU chemotherapy in anaplastic astrocytoma: Results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882)
-
Add time:07/29/2019 Source:sciencedirect.com
BackgroundIn a previous randomised EORTC study on adjuvant DIBROMODULCITOL (cas 10318-26-0) (DBD) and bichloroethylnitrosourea (BCNU) in adults with glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), a clinically significant trend towards a longer overall survival (OS) and a progression-free survival (PFS) was observed in the subgroup of AA. The aim of the present study was to test this adjuvant regimen in a larger number of AA patients.
We also recommend Trading Suppliers and Manufacturers of DIBROMODULCITOL (cas 10318-26-0). Pls Click Website Link as below: cas 10318-26-0 suppliers
Prev:Identification of guanine and adenine adducts in DNA alkylated by DIBROMODULCITOL (cas 10318-26-0) in vitro and in vivo
Next:Rat liver-mediated degradation of DIBROMODULCITOL (cas 10318-26-0)) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Metabolism and pharmacokinetics of DIBROMODULCITOL (cas 10318-26-0)(DBD, NSC-104800) in man—II. Pharmacokinetics of DBD08/05/2019
- The effect of DIBROMODULCITOL (cas 10318-26-0) on resting and dividing lymphoid cells08/04/2019
- The distribution of bromine content of DIBROMODULCITOL (cas 10318-26-0) in the central nervous system of patients with malignant gliomas08/03/2019
- DIBROMODULCITOL (cas 10318-26-0), mitomycin C and vinblastine (DMV) chemotherapy in advanced breast cancer08/02/2019
- APOPTOTIC AND MITOTIC ACTIVITY IN SQUAMOUS CELL CARCINOMA CELLS AFTER COMBINED MODALITY TREATMENT WITH γ-IRRADIATION AND DIBROMODULCITOL (cas 10318-26-0)08/01/2019
- DIBROMODULCITOL (cas 10318-26-0)07/31/2019
- Rat liver-mediated degradation of DIBROMODULCITOL (cas 10318-26-0)07/30/2019
- Identification of guanine and adenine adducts in DNA alkylated by DIBROMODULCITOL (cas 10318-26-0) in vitro and in vivo07/28/2019
